1
|
Mattei JC, Bouvier-Labit C, Barets D, Macagno N, Chocry M, Chibon F, Morando P, Rochwerger RA, Duffaud F, Olschwang S, Salas S, Jiguet-Jiglaire C. Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers (Basel) 2020; 12:E583. [PMID: 32138169 PMCID: PMC7139289 DOI: 10.3390/cancers12030583] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 02/24/2020] [Accepted: 02/28/2020] [Indexed: 11/17/2022] Open
Abstract
Soft tissue sarcoma (STS) are rare and aggressive tumours. Their classification includes numerous histological subtypes of frequent poor prognosis. Liposarcomas (LPS) are the most frequent type among them, and the aggressiveness and deep localization of dedifferentiated LPS are linked to high levels of recurrence. Current treatments available today lead to five-year overall survival has remained stuck around 60%-70% for the past three decades. Here, we highlight a correlation between Aurora kinasa A (AURKA) and AURKB mRNA overexpression and a low metastasis - free survival. AURKA and AURKB expression analysis at genomic and protein level on a 9-STS cell lines panel highlighted STS heterogeneity, especially in LPS subtype. AURKA and AURKB inhibition by RNAi and drug targeting with AMG 900, a pan Aurora Kinase inhibitor, in four LPS cell lines reduces cell survival and clonogenic proliferation, inducing apoptosis and polyploidy. When combined with doxorubicin, the standard treatment in STS, aurora kinases inhibitor can be considered as an enhancer of standard treatment or as an independent drug. Kinome analysis suggested its effect was linked to the inhibition of the MAP-kinase pathway, with differential drug resistance profiles depending on molecular characteristics of the tumor. Aurora Kinase inhibition by AMG 900 could be a promising therapy in STS.
Collapse
Affiliation(s)
- Jean Camille Mattei
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital Nord, Service d'Orthopédie et traumatologie, 13015 Marseille, France
| | - Corinne Bouvier-Labit
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, 13005 Marseille, France; (D.B.); (N.M.)
| | - Doriane Barets
- APHM, Hôpital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, 13005 Marseille, France; (D.B.); (N.M.)
| | - Nicolas Macagno
- APHM, Hôpital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, 13005 Marseille, France; (D.B.); (N.M.)
| | - Mathieu Chocry
- Aix-Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France; (M.C.); (P.M.)
| | | | - Philippe Morando
- Aix-Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France; (M.C.); (P.M.)
| | - Richard Alexandre Rochwerger
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital Nord, Service d'Orthopédie et traumatologie, 13015 Marseille, France
| | - Florence Duffaud
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital de la Timone, Service d’Oncologie adulte, 13005 Marseille, France
| | - Sylviane Olschwang
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital de la Timone, Département de Génétique Médicale, 13005 Marseille, France
- Ramsay Générale de Santé, Hôpital Clairval, Institut de Cancérologie, 13005 Marseille, France
| | - Sébastien Salas
- Aix-Marseille University, Inserm, MMG, 13005 Marseille, France; (J.C.M.); (C.B.-L.); (R.A.R.); (F.D.); (S.O.); (S.S.)
- APHM, Hôpital de la Timone, Service d’Oncologie adulte, 13005 Marseille, France
| | - Carine Jiguet-Jiglaire
- APHM, Hôpital de la Timone, Service d’Anatomie Pathologique et de Neuropathologie, 13005 Marseille, France; (D.B.); (N.M.)
- Aix-Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France; (M.C.); (P.M.)
- APHM, Centre de Ressources Biologiques, 13005 Marseille, France
| |
Collapse
|
2
|
Mareschal S, Ruminy P, Alcantara M, Villenet C, Figeac M, Dubois S, Bertrand P, Bouzelfen A, Viailly PJ, Penther D, Tilly H, Bastard C, Jardin F. Application of the cghRA framework to the genomic characterization of Diffuse Large B-Cell Lymphoma. Bioinformatics 2018; 33:2977-2985. [PMID: 28481978 DOI: 10.1093/bioinformatics/btx309] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 05/06/2017] [Indexed: 12/15/2022] Open
Abstract
Motivation Although sequencing-based technologies are becoming the new reference in genome analysis, comparative genomic hybridization arrays (aCGH) still constitute a simple and reliable approach for copy number analysis. The most powerful algorithms to analyze such data have been freely provided by the scientific community for many years, but combining them is a complex scripting task. Results The cghRA framework combines a user-friendly graphical interface and a powerful object-oriented command-line interface to handle a full aCGH analysis, as is illustrated in an original series of 107 Diffuse Large B-Cell Lymphomas. New algorithms for copy-number calling, polymorphism detection and minimal common region prioritization were also developed and validated. While their performances will only be demonstrated with aCGH, these algorithms could actually prove useful to any copy-number analysis, whatever the technique used. Availability and implementation R package and source for Linux, MS Windows and MacOS are freely available at http://bioinformatics.ovsa.fr/cghRA. Contact mareschal@ovsa.fr or fabrice.jardin@chb.unicancer.fr. Supplementary information Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Sylvain Mareschal
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Philippe Ruminy
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Marion Alcantara
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Céline Villenet
- Plate-Forme de Génomique Fonctionnelle et Structurale, Université de Lille II, 59000 Lille, France
| | - Martin Figeac
- Plate-Forme de Génomique Fonctionnelle et Structurale, Université de Lille II, 59000 Lille, France.,Cellule de Bioinformatique du Plateau Commun de Séquençage, CHRU de Lille, 59000 Lille, France
| | - Sydney Dubois
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Philippe Bertrand
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Abdelilah Bouzelfen
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Pierre-Julien Viailly
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Dominique Penther
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Hervé Tilly
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France
| | - Christian Bastard
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| | - Fabrice Jardin
- INSERM U1245 Team "Genomics and Biomarkers in Lymphoma and Solid Tumors," Centre Henri Becquerel, 76000 Rouen, France.,Normandie Université, 14000 Caen, France
| |
Collapse
|
3
|
Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res 2018; 20:28. [PMID: 29665859 PMCID: PMC5905168 DOI: 10.1186/s13058-018-0951-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 03/05/2018] [Indexed: 01/23/2023] Open
Abstract
Background The ataxia telangiectasia mutated (ATM) gene is a moderate-risk breast cancer susceptibility gene; germline loss-of-function variants are found in up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergo genetic testing. So far, no clear histopathological and molecular features of breast tumours occurring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumour signature may help in patient management. Methods To characterise hallmarks of ATM-associated tumours, we performed systematic pathology review of tumours from 21 participants from ataxia-telangiectasia families and 18 participants from HBOC families, as well as copy number profiling on a subset of 23 tumours. Morphology of ATM-associated tumours was compared with that of 599 patients with no BRCA1 and BRCA2 mutations from a hospital-based series, as well as with data from The Cancer Genome Atlas. Absolute copy number and loss of heterozygosity (LOH) profiles were obtained from the OncoScan SNP array. In addition, we performed whole-genome sequencing on four tumours from ATM loss-of-function variant carriers with available frozen material. Results We found that ATM-associated tumours belong mostly to the luminal B subtype, are tetraploid and show LOH at the ATM locus at 11q22–23. Unlike tumours in which BRCA1 or BRCA2 is inactivated, tumours arising in ATM deleterious variant carriers are not associated with increased large-scale genomic instability as measured by the large-scale state transitions signature. Losses at 13q14.11-q14.3, 17p13.2-p12, 21p11.2-p11.1 and 22q11.23 were observed. Somatic alterations at these loci may therefore represent biomarkers for ATM testing and harbour driver mutations in potentially ‘druggable’ genes that would allow patients to be directed towards tailored therapeutic strategies. Conclusions Although ATM is involved in the DNA damage response, ATM-associated tumours are distinct from BRCA1-associated tumours in terms of morphological characteristics and genomic alterations, and they are also distinguishable from sporadic breast tumours, thus opening up the possibility to identify ATM variant carriers outside the ataxia-telangiectasia disorder and direct them towards effective cancer risk management and therapeutic strategies. Electronic supplementary material The online version of this article (10.1186/s13058-018-0951-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anne-Laure Renault
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Noura Mebirouk
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | | | | | - Eve Cavaciuti
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Dorothée Le Gal
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Elodie Girard
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Tatiana Popova
- Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,INSERM U830, Paris, France
| | - Philippe La Rosa
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Juana Beauvallet
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Séverine Eon-Marchais
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Marie-Gabrielle Dondon
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | | | | | - Walid Chemlali
- Unité de Pharmacogénomique, Institut Curie, Paris, France
| | - Virginie Raynal
- Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, Paris, France
| | - Martine Labbé
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Ivan Bièche
- Unité de Pharmacogénomique, Institut Curie, Paris, France
| | - Sylvain Baulande
- Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, Paris, France
| | | | - Pascaline Berthet
- Unité de Pathologie Gynécologique, Centre François Baclesse, Caen, France
| | - Olivier Caron
- Service d'Oncologie Génétique, Gustave Roussy, Villejuif, France
| | | | - Laurence Faivre
- Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.,Oncogénétique, Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France
| | - Marc Fresnay
- Département d'Hématologie et d'Oncologie Médicale, CLCC Antoine Lacassagne, Nice, France
| | | | - Paul Gesta
- Service d'Oncogénétique Régional Poitou-Charentes, Centre Hospitalier Georges-Renon, Niort, France
| | - Nicolas Janin
- Service de Génétique, Clinique Universitaire Saint-Luc, Brussels, Belgium
| | - Sophie Lejeune
- Service de Génétique Clinique Guy Fontaine, Hôpital Jeanne de Flandre, Lille, France
| | - Christine Maugard
- Laboratoire de Diagnostic Génétique, UF1422 Oncogénétique Moléculaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Oncogénétique Evaluation familiale et suivi, UF6948 Oncogénétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Sébastien Moutton
- Laboratoire Maladies Rares: Génétique et Métabolisme, CHU de Bordeaux-GH Pellegrin, Bordeaux, France
| | | | - Hélène Zattara
- Département de Génétique, Hôpital de la Timone, Marseille, France
| | | | | | - Isabelle Coupier
- Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.,Unité d'Oncogénétique, ICM Val d'Aurelle, Montpellier, France
| | | | | | | | - Georgia Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Janet Hall
- UMR INSERM 1052, Lyon, France.,CNRS 5286, Lyon, France.,Centre de Recherche en Cancérologie de Lyon, Lyon, France
| | | | - Dominique Stoppa-Lyonnet
- INSERM U830, Paris, France.,Service de Génétique, Institut Curie, Paris, France.,Université Paris Descartes, Paris, France
| | - Nadine Andrieu
- INSERM, U900, Paris, France.,Institut Curie, Paris, France.,Mines Paris Tech, Fontainebleau, France.,PSL Research University, Paris, France
| | - Fabienne Lesueur
- INSERM, U900, Paris, France. .,Institut Curie, Paris, France. .,Mines Paris Tech, Fontainebleau, France. .,PSL Research University, Paris, France.
| |
Collapse
|
4
|
Abstract
Opsoclonus myoclonus syndrome (OMS), often called "dancing eyed syndrome," is a rare neurological condition associated with neuroblastoma in the majority of all childhood cases. Genomic copy number profiles have shown to be of prognostic significance for neuroblastoma patients. The aim of this retrospective multicenter study was to analyze the genomic copy number profiles of tumors from children with neuroblastoma presenting with OMS at diagnosis. In 44 cases of neuroblastoma associated with OMS, overall genomic profiling by either array-comparative genomic hybridization or single nucleotide polymorphism array proved successful in 91% of the cases, distinguishing tumors harboring segmental chromosome alterations from those with numerical chromosome alterations only. A total of 23/44 (52%) tumors showed an segmental chromosome alterations genomic profile, 16/44 (36%) an numerical chromosome alterations genomic profile, and 1 case displayed an atypical profile (12q amplicon). No recurrently small interstitial copy number alterations were identified. With no tumor relapse nor disease-related deaths, the overall genomic profile was not of prognostic impact with regard to the oncological outcome in this series of patients. Thus, the observation of an excellent oncological outcome, even for those with an unfavorable genomic profile of neuroblastoma, supports the hypothesis that an immune response might be involved in tumor control in these patients with OMS.
Collapse
|
5
|
Durrieu-Gaillard S, Dumay-Odelot H, Boldina G, Tourasse NJ, Allard D, André F, Macari F, Choquet A, Lagarde P, Drutel G, Leste-Lasserre T, Petitet M, Lesluyes T, Lartigue-Faustin L, Dupuy JW, Chibon F, Roeder RG, Joubert D, Vagner S, Teichmann M. Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. Cell Cycle 2018; 17:605-615. [PMID: 29171785 DOI: 10.1080/15384101.2017.1405881] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
RNA polymerase (Pol) III transcribes small untranslated RNAs that are essential for cellular homeostasis and growth. Its activity is regulated by inactivation of tumor suppressor proteins and overexpression of the oncogene c-MYC, but the concerted action of these tumor-promoting factors on Pol III transcription has not yet been assessed. In order to comprehensively analyse the regulation of Pol III transcription during tumorigenesis we employ a model system that relies on the expression of five genetic elements to achieve cellular transformation. Expression of these elements in six distinct transformation intermediate cell lines leads to the inactivation of TP53, RB1, and protein phosphatase 2A, as well as the activation of RAS and the protection of telomeres by TERT, thereby conducting to full tumoral transformation of IMR90 fibroblasts. Transformation is accompanied by moderately enhanced levels of a subset of Pol III-transcribed RNAs (7SK; MRP; H1). In addition, mRNA and/or protein levels of several Pol III subunits and transcription factors are upregulated, including increased protein levels of TFIIIB and TFIIIC subunits, of SNAPC1 and of Pol III subunits. Strikingly, the expression of POLR3G and of SNAPC1 is strongly enhanced during transformation in this cellular transformation model. Collectively, our data indicate that increased expression of several components of the Pol III transcription system accompanied by a 2-fold increase in steady state levels of a subset of Pol III RNAs is sufficient for sustaining tumor formation.
Collapse
Affiliation(s)
- Stéphanie Durrieu-Gaillard
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France.,b INSERM, U1212 - CNRS UMR 5320 , ARNA Laboratory , F-33000 Bordeaux , France
| | - Hélène Dumay-Odelot
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France.,b INSERM, U1212 - CNRS UMR 5320 , ARNA Laboratory , F-33000 Bordeaux , France
| | - Galina Boldina
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France.,b INSERM, U1212 - CNRS UMR 5320 , ARNA Laboratory , F-33000 Bordeaux , France.,c Institut Gustave Roussy , INSERM U981 , F-94805 Villejuif , France
| | - Nicolas J Tourasse
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France.,b INSERM, U1212 - CNRS UMR 5320 , ARNA Laboratory , F-33000 Bordeaux , France
| | - Delphine Allard
- c Institut Gustave Roussy , INSERM U981 , F-94805 Villejuif , France
| | - Fabrice André
- c Institut Gustave Roussy , INSERM U981 , F-94805 Villejuif , France
| | - Françoise Macari
- d Institut de Génomique Fonctionnelle , UMR 5203 CNRS , F-34000 Montpellier , France
| | - Armelle Choquet
- d Institut de Génomique Fonctionnelle , UMR 5203 CNRS , F-34000 Montpellier , France
| | - Pauline Lagarde
- e Department of Biopathology , Institut Bergonié , Molecular Pathology Unit , F-33000 Bordeaux , France.,f Génétique et Biologie des Sarcomes- INSERM U916 , F- 33000 Bordeaux , France.,g Université de Bordeaux , F-33076 Bordeaux , France
| | - Guillaume Drutel
- h NeuroCentre François Magendie , INSERM U862 , F-33077 Bordeaux , France
| | | | - Marion Petitet
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France
| | - Tom Lesluyes
- e Department of Biopathology , Institut Bergonié , Molecular Pathology Unit , F-33000 Bordeaux , France.,f Génétique et Biologie des Sarcomes- INSERM U916 , F- 33000 Bordeaux , France
| | - Lydia Lartigue-Faustin
- e Department of Biopathology , Institut Bergonié , Molecular Pathology Unit , F-33000 Bordeaux , France.,f Génétique et Biologie des Sarcomes- INSERM U916 , F- 33000 Bordeaux , France
| | - Jean-William Dupuy
- i Université de Bordeaux , Plateforme Protéome - Centre Génomique Fonctionnelle Bordeaux , 33076 Bordeaux , France
| | - Frédéric Chibon
- e Department of Biopathology , Institut Bergonié , Molecular Pathology Unit , F-33000 Bordeaux , France.,f Génétique et Biologie des Sarcomes- INSERM U916 , F- 33000 Bordeaux , France
| | - Robert G Roeder
- j The Rockefeller University , 1230 York Avenue, New York , NY 10065 , USA
| | - Dominique Joubert
- d Institut de Génomique Fonctionnelle , UMR 5203 CNRS , F-34000 Montpellier , France
| | - Stéphan Vagner
- c Institut Gustave Roussy , INSERM U981 , F-94805 Villejuif , France.,k Institut Curie , CNRS UMR 3348, F-91405 Orsay , France
| | - Martin Teichmann
- a Université de Bordeaux , ARNA Laboratory , F-33076 Bordeaux , France.,b INSERM, U1212 - CNRS UMR 5320 , ARNA Laboratory , F-33000 Bordeaux , France
| |
Collapse
|
6
|
Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS One 2017; 12:e0185190. [PMID: 28945781 PMCID: PMC5612658 DOI: 10.1371/journal.pone.0185190] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Accepted: 09/05/2017] [Indexed: 01/01/2023] Open
Abstract
Purpose This study investigated relationships between neuroblastomas (NBs) imaging phenotypes, tumor genomic profile and patient outcome. Patients and methods This IRB-approved retrospective observational study included 133 NB patients (73 M, 60 F; median age 15 months, range 0–151) treated in a single institution between 1998 and 2012. A consensus review of imaging (CT-scan, MRI) categorized tumors according to both the primarily involved compartment (i.e., neck, chest, abdomen or pelvis) and the sympathetic anatomical structure the tumors rose from (i.e., cervical, paravertebral or periarterial chains, or adrenal gland). Tumor shape, volume and image-defined surgical risk factors (IDRFs) at diagnosis were recorded. Genomic profiles were assessed using array-based comparative genomic hybridization and divided into three groups: “numerical-only chromosome alterations” (NCA), “segmental chromosome alterations” (SCA) and “MYCN amplification” (MNA). Statistical analyses included Kruskal–Wallis, Chi2 and Fisher’s exact tests and the Kaplan-Meier method with log-rank tests and Cox model for univariate and multivariate survival analyses. Results A significant association between the sympathetic structure origin of tumors and genomic profiles was demonstrated. NBs arising from cervical sympathetic chains were all NCA. Paravertebral NBs were NCA or SCA in 75% and 25%, respectively and none were MNA. Periarterial NBs were NCA, SCA or MNA in 33%, 56% and 11%, respectively. Adrenal NBs were NCA, SCA or MNA in 16%, 36% and 48%, respectively. Among MNA NBs, 92% originated from the adrenal gland. The sympathetic anatomical classification was significantly better correlated to overall survival than the compartmental classification (P < .0003). The tumor volume of MNA NBs was significantly higher than NCA or SCA NBs (P < .0001). Patients with initial volume less than 160 mL had significantly better overall survival (P < .009). A “single mass” pattern was significantly more frequent in NCA NBs (P = .0003). The number of IDRFs was significantly higher in MNA NBs (P < .0001). Conclusion Imaging phenotypes of neuroblastomas, including tumor origin along the sympathetic system, correlate with tumor genomic profile and patient outcome.
Collapse
|
7
|
Tebel K, Boldt V, Steininger A, Port M, Ebert G, Ullmann R. GenomeCAT: a versatile tool for the analysis and integrative visualization of DNA copy number variants. BMC Bioinformatics 2017; 18:19. [PMID: 28061750 PMCID: PMC5217618 DOI: 10.1186/s12859-016-1430-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 12/16/2016] [Indexed: 12/19/2022] Open
Abstract
Background The analysis of DNA copy number variants (CNV) has increasing impact in the field of genetic diagnostics and research. However, the interpretation of CNV data derived from high resolution array CGH or NGS platforms is complicated by the considerable variability of the human genome. Therefore, tools for multidimensional data analysis and comparison of patient cohorts are needed to assist in the discrimination of clinically relevant CNVs from others. Results We developed GenomeCAT, a standalone Java application for the analysis and integrative visualization of CNVs. GenomeCAT is composed of three modules dedicated to the inspection of single cases, comparative analysis of multidimensional data and group comparisons aiming at the identification of recurrent aberrations in patients sharing the same phenotype, respectively. Its flexible import options ease the comparative analysis of own results derived from microarray or NGS platforms with data from literature or public depositories. Multidimensional data obtained from different experiment types can be merged into a common data matrix to enable common visualization and analysis. All results are stored in the integrated MySQL database, but can also be exported as tab delimited files for further statistical calculations in external programs. Conclusions GenomeCAT offers a broad spectrum of visualization and analysis tools that assist in the evaluation of CNVs in the context of other experiment data and annotations. The use of GenomeCAT does not require any specialized computer skills. The various R packages implemented for data analysis are fully integrated into GenomeCATs graphical user interface and the installation process is supported by a wizard. The flexibility in terms of data import and export in combination with the ability to create a common data matrix makes the program also well suited as an interface between genomic data from heterogeneous sources and external software tools. Due to the modular architecture the functionality of GenomeCAT can be easily extended by further R packages or customized plug-ins to meet future requirements. Electronic supplementary material The online version of this article (doi:10.1186/s12859-016-1430-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Katrin Tebel
- Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany
| | - Vivien Boldt
- Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.,Department of Biology, Chemistry and Pharmacy, Free University Berlin, 14195, Berlin, Germany
| | - Anne Steininger
- Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.,Department of Biology, Chemistry and Pharmacy, Free University Berlin, 14195, Berlin, Germany
| | - Matthias Port
- Institut für Radiobiologie der Bundeswehr in Verb. mit der Universität Ulm, 80937, Munich, Germany
| | - Grit Ebert
- Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.,Department of Biology, Chemistry and Pharmacy, Free University Berlin, 14195, Berlin, Germany
| | - Reinhard Ullmann
- Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany. .,Institut für Radiobiologie der Bundeswehr in Verb. mit der Universität Ulm, 80937, Munich, Germany.
| |
Collapse
|
8
|
Laé M, La Rosa P, Mandel J, Reyal F, Hupé P, Terrier P, Couturier J. Whole-genome profiling helps to classify phyllodes tumours of the breast. J Clin Pathol 2016; 69:1081-1087. [DOI: 10.1136/jclinpath-2016-203684] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 04/21/2016] [Accepted: 04/28/2016] [Indexed: 11/03/2022]
|
9
|
Cui H, Dhroso A, Johnson N, Korkin D. The variation game: Cracking complex genetic disorders with NGS and omics data. Methods 2015; 79-80:18-31. [PMID: 25944472 DOI: 10.1016/j.ymeth.2015.04.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Revised: 03/27/2015] [Accepted: 04/17/2015] [Indexed: 12/14/2022] Open
Abstract
Tremendous advances in Next Generation Sequencing (NGS) and high-throughput omics methods have brought us one step closer towards mechanistic understanding of the complex disease at the molecular level. In this review, we discuss four basic regulatory mechanisms implicated in complex genetic diseases, such as cancer, neurological disorders, heart disease, diabetes, and many others. The mechanisms, including genetic variations, copy-number variations, posttranscriptional variations, and epigenetic variations, can be detected using a variety of NGS methods. We propose that malfunctions detected in these mechanisms are not necessarily independent, since these malfunctions are often found associated with the same disease and targeting the same gene, group of genes, or functional pathway. As an example, we discuss possible rewiring effects of the cancer-associated genetic, structural, and posttranscriptional variations on the protein-protein interaction (PPI) network centered around P53 protein. The review highlights multi-layered complexity of common genetic disorders and suggests that integration of NGS and omics data is a critical step in developing new computational methods capable of deciphering this complexity.
Collapse
Affiliation(s)
- Hongzhu Cui
- Department of Computer Science, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States
| | - Andi Dhroso
- Department of Computer Science, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States
| | - Nathan Johnson
- Department of Computer Science, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States
| | - Dmitry Korkin
- Department of Computer Science, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States; Bioinformatics and Computational Biology Program, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States
| |
Collapse
|
10
|
aCGH-MAS: analysis of aCGH by means of multiagent system. BIOMED RESEARCH INTERNATIONAL 2015; 2015:194624. [PMID: 25874203 PMCID: PMC4385609 DOI: 10.1155/2015/194624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Revised: 10/31/2014] [Accepted: 11/17/2014] [Indexed: 12/02/2022]
Abstract
There are currently different techniques, such as CGH arrays, to study genetic variations in patients. CGH arrays analyze gains and losses in different regions in the chromosome. Regions with gains or losses in pathologies are important for selecting relevant genes or CNVs (copy-number variations) associated with the variations detected within chromosomes. Information corresponding to mutations, genes, proteins, variations, CNVs, and diseases can be found in different databases and it would be of interest to incorporate information of different sources to extract relevant information. This work proposes a multiagent system to manage the information of aCGH arrays, with the aim of providing an intuitive and extensible system to analyze and interpret the results. The agent roles integrate statistical techniques to select relevant variations and visualization techniques for the interpretation of the final results and to extract relevant information from different sources of information by applying a CBR system.
Collapse
|
11
|
Newton R, Wernisch L. A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships. PLoS One 2014; 9:e105522. [PMID: 25148247 PMCID: PMC4141782 DOI: 10.1371/journal.pone.0105522] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Accepted: 07/21/2014] [Indexed: 12/25/2022] Open
Abstract
Inferring gene regulatory relationships from observational data is challenging. Manipulation and intervention is often required to unravel causal relationships unambiguously. However, gene copy number changes, as they frequently occur in cancer cells, might be considered natural manipulation experiments on gene expression. An increasing number of data sets on matched array comparative genomic hybridisation and transcriptomics experiments from a variety of cancer pathologies are becoming publicly available. Here we explore the potential of a meta-analysis of thirty such data sets. The aim of our analysis was to assess the potential of in silico inference of trans-acting gene regulatory relationships from this type of data. We found sufficient correlation signal in the data to infer gene regulatory relationships, with interesting similarities between data sets. A number of genes had highly correlated copy number and expression changes in many of the data sets and we present predicted potential trans-acted regulatory relationships for each of these genes. The study also investigates to what extent heterogeneity between cell types and between pathologies determines the number of statistically significant predictions available from a meta-analysis of experiments.
Collapse
Affiliation(s)
- Richard Newton
- Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
- * E-mail:
| | - Lorenz Wernisch
- Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom
| |
Collapse
|
12
|
Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, Mosseri V, Thebaud E, Gambart M, Plantaz D, Marabelle A, Coze C, Rialland X, Fasola S, Lapouble E, Fréneaux P, Peuchmaur M, Michon J, Delattre O, Schleiermacher G. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. PLoS One 2014; 9:e101990. [PMID: 25013904 PMCID: PMC4094484 DOI: 10.1371/journal.pone.0101990] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Accepted: 06/13/2014] [Indexed: 01/01/2023] Open
Abstract
Background Somatically acquired genomic alterations with MYCN amplification (MNA) are key features of neuroblastoma (NB), the most common extra-cranial malignant tumour of childhood. Little is known about the frequency, clinical characteristics and outcome of NBs harbouring genomic amplification(s) distinct from MYCN. Methods Genomic profiles of 1100 NBs from French centres studied by array-CGH were re-examined specifically to identify regional amplifications. Patients were included if amplifications distinct from the MYCN locus were seen. A subset of NBs treated at Institut Curie and harbouring MNA as determined by array-CGH without other amplification was also studied. Clinical and histology data were retrospectively collected. Results In total, 56 patients were included and categorised into 3 groups. Group 1 (n = 8) presented regional amplification(s) without MNA. Locus 12q13-14 was a recurrent amplified region (4/8 cases). This group was heterogeneous in terms of INSS stages, primary localisations and histology, with atypical clinical features. Group 2 (n = 26) had MNA as well as other regional amplifications. These patients shared clinical features of those of a group of NBs MYCN amplified (Group 3, n = 22). Overall survival for group 1 was better than that of groups 2 and 3 (5 year OS: 87.5%±11% vs 34.9%±7%, log-rank p<0.05). Conclusion NBs harbouring regional amplification(s) without MNA are rare and seem to show atypical features in clinical presentation and genomic profile. Further high resolution genetic explorations are justified in this heterogeneous group, especially when considering these alterations as predictive markers for targeted therapy.
Collapse
Affiliation(s)
- Anne Guimier
- Institut Curie, Département de Pédiatrie, Paris, France
| | | | - Gaëlle Pierron
- Institut Curie, Unité de Génétique Somatique, Paris, France
| | | | | | - Valérie Combaret
- Centre Léon Bérard, Laboratoire de recherche translationnelle, Lyon, France
| | | | - Estelle Thebaud
- CHU Nantes, Service d'Hémato-Oncologie Pédiatrique, Nantes, France
| | - Marion Gambart
- CHU Toulouse, Service d'Hémato-Oncologie Pédiatrique, Toulouse, France
| | - Dominique Plantaz
- CHU Grenoble, Service d'Hémato-Oncologie Pédiatrique, Grenoble, France
| | - Aurélien Marabelle
- Institut d'Hématologie et d'Oncologie Pédiatrique, Centre de Lutte contre le Cancer Léon Bérard, Lyon, France
| | - Carole Coze
- Aix-Marseille Univ et APHM, Hôpital d'Enfants de La Timone, Service d'Hématologie-Oncologie Pédiatrique, Marseille, France
| | - Xavier Rialland
- CHU Angers, Service d'Hémato-Oncologie Pédiatrique, Angers, France
| | - Sylvie Fasola
- Hôpital Trousseau, Service d'Hémato-Oncologie Pédiatrique, Paris, France
| | - Eve Lapouble
- Institut Curie, Unité de Génétique Somatique, Paris, France
| | - Paul Fréneaux
- Institut Curie, Laboratoire d'anatomie pathologique, Paris, France
| | - Michel Peuchmaur
- APHP, hôpital Universitaire Robert Debré, Service de Pathologie, Paris, France, et Université Diderot Paris 7, Sorbonne Paris Cité, Paris, France
| | - Jean Michon
- Institut Curie, Département de Pédiatrie, Paris, France
| | - Olivier Delattre
- INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
| | - Gudrun Schleiermacher
- Institut Curie, Département de Pédiatrie, Paris, France
- INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
- * E-mail:
| |
Collapse
|
13
|
Hocking TD, Boeva V, Rigaill G, Schleiermacher G, Janoueix-Lerosey I, Delattre O, Richer W, Bourdeaut F, Suguro M, Seto M, Bach F, Vert JP. SegAnnDB: interactive Web-based genomic segmentation. ACTA ACUST UNITED AC 2014; 30:1539-46. [PMID: 24493034 PMCID: PMC4029035 DOI: 10.1093/bioinformatics/btu072] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
MOTIVATION DNA copy number profiles characterize regions of chromosome gains, losses and breakpoints in tumor genomes. Although many models have been proposed to detect these alterations, it is not clear which model is appropriate before visual inspection the signal, noise and models for a particular profile. RESULTS We propose SegAnnDB, a Web-based computer vision system for genomic segmentation: first, visually inspect the profiles and manually annotate altered regions, then SegAnnDB determines the precise alteration locations using a mathematical model of the data and annotations. SegAnnDB facilitates collaboration between biologists and bioinformaticians, and uses the University of California, Santa Cruz genome browser to visualize copy number alterations alongside known genes. AVAILABILITY AND IMPLEMENTATION The breakpoints project on INRIA GForge hosts the source code, an Amazon Machine Image can be launched and a demonstration Web site is http://bioviz.rocq.inria.fr.
Collapse
Affiliation(s)
- Toby D Hocking
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Valentina Boeva
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Guillem Rigaill
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Gudrun Schleiermacher
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Isabelle Janoueix-Lerosey
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Olivier Delattre
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Wilfrid Richer
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Franck Bourdeaut
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Miyuki Suguro
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Masao Seto
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Francis Bach
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| | - Jean-Philippe Vert
- Department of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, FranceDepartment of Computer Science, Tokyo Institute of Technology, Tokyo 152-8552, Japan, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, INSERM U900, Paris F-75248, France, Mines ParisTech, Centre for Computational Biology, 77300 Fontainebleau, Unité de Recherche en Génomique Végétale INRA-CNRS-Université d'Evry Val d'Essonne, Évry 91057, France, INSERM U830, Paris F-75248, France, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya-city 464-8681, Japan and INRIA-Sierra Project-Team, Département d'Informatique de l'École Normale Supérieure, Paris F-75013, France
| |
Collapse
|
14
|
Brito I, Hupé P, Neuvial P, Barillot E. Stability-based comparison of class discovery methods for DNA copy number profiles. PLoS One 2013; 8:e81458. [PMID: 24339933 PMCID: PMC3855312 DOI: 10.1371/journal.pone.0081458] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Accepted: 10/22/2013] [Indexed: 11/19/2022] Open
Abstract
MOTIVATION Array-CGH can be used to determine DNA copy number, imbalances in which are a fundamental factor in the genesis and progression of tumors. The discovery of classes with similar patterns of array-CGH profiles therefore adds to our understanding of cancer and the treatment of patients. Various input data representations for array-CGH, dissimilarity measures between tumor samples and clustering algorithms may be used for this purpose. The choice between procedures is often difficult. An evaluation procedure is therefore required to select the best class discovery method (combination of one input data representation, one dissimilarity measure and one clustering algorithm) for array-CGH. Robustness of the resulting classes is a common requirement, but no stability-based comparison of class discovery methods for array-CGH profiles has ever been reported. RESULTS We applied several class discovery methods and evaluated the stability of their solutions, with a modified version of Bertoni's [Formula: see text]-based test [1]. Our version relaxes the assumption of independency required by original Bertoni's [Formula: see text]-based test. We conclude that Minimal Regions of alteration (a concept introduced by [2]) for input data representation, sim [3] or agree [4] for dissimilarity measure and the use of average group distance in the clustering algorithm produce the most robust classes of array-CGH profiles. AVAILABILITY The software is available from http://bioinfo.curie.fr/projects/cgh-clustering. It has also been partly integrated into "Visualization and analysis of array-CGH"(VAMP)[5]. The data sets used are publicly available from ACTuDB [6].
Collapse
Affiliation(s)
- Isabel Brito
- Institut Curie, Paris, France
- INSERM, U900, Paris, France
- Mines ParisTech, Fontainebleau, France
| | - Philippe Hupé
- Institut Curie, Paris, France
- INSERM, U900, Paris, France
- Mines ParisTech, Fontainebleau, France
- CNRS UMR144, Paris, France
| | - Pierre Neuvial
- Laboratoire Statistique & Génome, Université d′Évry Val d′Essonne, UMR CNRS 8071-USC INRA, Évry, France
| | - Emmanuel Barillot
- Institut Curie, Paris, France
- INSERM, U900, Paris, France
- Mines ParisTech, Fontainebleau, France
| |
Collapse
|
15
|
Prognostic value of PLAGL1-specific CpG site methylation in soft-tissue sarcomas. PLoS One 2013; 8:e80741. [PMID: 24260468 PMCID: PMC3829972 DOI: 10.1371/journal.pone.0080741] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 10/06/2013] [Indexed: 12/25/2022] Open
Abstract
Soft tissue sarcomas (STS) are rare, complex tumors with a poor prognosis. The identification of new prognostic biomarkers is needed to improve patient management. Our aim was to determine the methylation status of the 118 CpG sites in the PLAGL1 tumor-suppressor gene P1 CpG island promoter and study the potential prognostic impact of PLAGL1 promoter methylation CpG sites in STS. Training cohorts constituted of 28 undifferentiated sarcomas (US) and 35 leiomyosarcomas (LMS) were studied. PLAGL1 mRNA expression was investigated by microarray analysis and validated by RT-qPCR. Pyrosequencing was used to analyze quantitative methylation of the PLAGL1 promoter. Associations between global promoter or specific CpG site methylation and mRNA expression were evaluated using Pearson's product moment correlation coefficient. Cox univariate and multivariate proportional hazard models were used to assess the predictive power of CpG site methylation status. Sixteen CpG sites associated with PLAGL1 mRNA expression were identified in US and 6 in LMS. Statistical analyses revealed an association between CpG107 methylation status and both overall and metastasis-free survival in US, which was confirmed in a validation cohort of 37 US. The exhaustive study of P1 PLAGL1 promoter methylation identified a specific CpG site methylation correlated with mRNA expression, which was predictive for both metastasis-free and overall survival and may constitute the first US-specific biomarker. Such a biomarker may be relevant for identifying patients likely to derive greater benefit from treatment.
Collapse
|
16
|
Cassoux N, Rodrigues MJ, Plancher C, Asselain B, Levy-Gabriel C, Lumbroso-Le Rouic L, Piperno-Neumann S, Dendale R, Sastre X, Desjardins L, Couturier J. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol 2013; 98:769-74. [PMID: 24169649 PMCID: PMC4033183 DOI: 10.1136/bjophthalmol-2013-303867] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Objective This study investigated the capacity of genetic analysis of uveal melanoma samples to identify high-risk patients and discusses its clinical implications. Methods Patients with posterior uveal melanoma were prospectively enrolled. Tumour samples were derived from enucleated globe, fine-needle aspirates or endoresection. Chromosome 3 and 8 status was determined by array comparative genomic hybridisation (array-CGH). Patients were followed after treatment to detect metastasis. Results Four groups were classified by array-CGH. Patients were divided into disomy 3 and normal chromosome 8 (D3/8nl), disomy 3 and 8q gain (D3/8g), monosomy 3 and normal chromosome 8 (M3/8nl) and monosomy 3 and 8 or 8q gain (M3/8g). Median follow-up was 28 months (range: 1–147 months). At the end of the study, 128 patients (33.7%) had developed metastasis and 96 patients had died. Univariate Cox proportional hazard analysis showed that factors associated with metastasis included basal tumour diameter p=0.0007, tumour thickness p=0.01, mixed/epithelioid cell type p=0.0009 and genomic data p<0.0001. High-risk profile was more strongly associated with metastasis than the other prognostic factors p<0.001. Multivariate Cox modelling analysis showed that the status of chromosomes 3 and 8 were the only two variables that independently contributed to prognosis: monosomy 3 alone p=0.001 and monosomy 3 and 8q gain p<0.0001. Conclusions Array-CGH allowed identification of three prognostic groups with low, intermediate and high risk of developing metastasis. Array-CGH is a reliable and inexpensive method for uveal melanoma prognosis. This method is now currently used in France.
Collapse
Affiliation(s)
- Nathalie Cassoux
- Department of Surgical Oncology, Institut Curie 26 rue d'Ulm, Paris, France
| | | | - Corine Plancher
- Department of Biostatistics, Institut Curie 25 rue d'Ulm, Paris, France
| | - Bernard Asselain
- Department of Biostatistics, Institut Curie 25 rue d'Ulm, Paris, France
| | | | | | | | - Rémi Dendale
- Department of Radiotherapy Orsay Proton therapy, Center Institut Curie Orsay, Paris, France
| | - Xavier Sastre
- Department of Pathology, Institut Curie 25 rue d'Ulm, Paris, France
| | | | - Jérôme Couturier
- Department of Genetics, Institut Curie 25 rue d'Ulm, Paris, France
| |
Collapse
|
17
|
Goh XY, Newton R, Wernisch L, Fitzgerald R. Testing the utility of an integrated analysis of copy number and transcriptomics datasets for inferring gene regulatory relationships. PLoS One 2013; 8:e63780. [PMID: 23737949 PMCID: PMC3667814 DOI: 10.1371/journal.pone.0063780] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Accepted: 04/07/2013] [Indexed: 12/31/2022] Open
Abstract
Correlation patterns between matched copy number variation and gene expression data in cancer samples enable the inference of causal gene regulatory relationships by exploiting the natural randomization of such systems. The aim of this study was to test and verify experimentally the accuracy of a causal inference approach based on genomic randomization using esophageal cancer samples. Two candidates with strong regulatory effects emerging from our analysis are components of growth factor receptors, and implicated in cancer development, namely ERBB2 and FGFR2. We tested experimentally two ERBB2 and three FGFR2 regulated interactions predicted by the statistical analysis, all of which were confirmed. We also applied the method in a meta-analysis of 10 cancer datasets and tested 15 of the predicted regulatory interactions experimentally. Three additional predicted ERBB2 regulated interactions were confirmed, as well as interactions regulated by ARPC1A and FANCG. Overall, two thirds of experimentally tested predictions were confirmed.
Collapse
Affiliation(s)
- Xin Yi Goh
- Medical Research Council Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, United Kingdom
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | - Richard Newton
- Medical Research Council Biostatistics Unit, Cambridge, United Kingdom
- * E-mail:
| | - Lorenz Wernisch
- Medical Research Council Biostatistics Unit, Cambridge, United Kingdom
| | - Rebecca Fitzgerald
- Medical Research Council Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, United Kingdom
| |
Collapse
|
18
|
Knierim E, Schwarz JM, Schuelke M, Seelow D. CNVinspector: a web-based tool for the interactive evaluation of copy number variations in single patients and in cohorts. J Med Genet 2013; 50:529-33. [PMID: 23729504 DOI: 10.1136/jmedgenet-2012-101497] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVES Many genetic disorders are caused by copy number variations (CNVs) in the human genome. However, the large number of benign CNV polymorphisms makes it difficult to delineate causative variants for a certain disease phenotype. Hence, we set out to create software that accumulates and visualises locus-specific knowledge and enables clinicians to study their own CNVs in the context of known polymorphisms and disease variants. METHODS CNV data from healthy cohorts (Database of Genomic Variants) and from disease-related databases (DECIPHER) were integrated into a joint resource. Data are presented in an interactive web-based application that allows inspection, evaluation and filtering of CNVs in single individuals or in entire cohorts. RESULTS CNVinspector provides simple interfaces to upload CNV data, compare them with own or published control data and visualise the results in graphical interfaces. Beyond choosing control data from different public studies, platforms and methods, dedicated filter options allow the detection of CNVs that are either enriched in patients or depleted in controls. Alternatively, a search can be restricted to those CNVs that appear in individuals of similar clinical phenotype. For each gene of interest within a CNV, we provide a link to NCBI, ENSEMBL and the GeneDistiller search engine to browse for potential disease-associated genes. CONCLUSIONS With its user-friendly handling, the integration of control data and the filtering options, CNVinspector will facilitate the daily work of clinical geneticists and accelerate the delineation of new syndromes and gene functions. CNVinspector is freely accessible under http://www.cnvinspector.org.
Collapse
|
19
|
Hocking TD, Schleiermacher G, Janoueix-Lerosey I, Boeva V, Cappo J, Delattre O, Bach F, Vert JP. Learning smoothing models of copy number profiles using breakpoint annotations. BMC Bioinformatics 2013; 14:164. [PMID: 23697330 PMCID: PMC3712326 DOI: 10.1186/1471-2105-14-164] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Accepted: 05/02/2013] [Indexed: 11/14/2022] Open
Abstract
Background Many models have been proposed to detect copy number alterations in chromosomal copy number profiles, but it is usually not obvious to decide which is most effective for a given data set. Furthermore, most methods have a smoothing parameter that determines the number of breakpoints and must be chosen using various heuristics. Results We present three contributions for copy number profile smoothing model selection. First, we propose to select the model and degree of smoothness that maximizes agreement with visual breakpoint region annotations. Second, we develop cross-validation procedures to estimate the error of the trained models. Third, we apply these methods to compare 17 smoothing models on a new database of 575 annotated neuroblastoma copy number profiles, which we make available as a public benchmark for testing new algorithms. Conclusions Whereas previous studies have been qualitative or limited to simulated data, our annotation-guided approach is quantitative and suggests which algorithms are fastest and most accurate in practice on real data. In the neuroblastoma data, the equivalent pelt.n and cghseg.k methods were the best breakpoint detectors, and exhibited reasonable computation times.
Collapse
|
20
|
Schroeder MP, Gonzalez-Perez A, Lopez-Bigas N. Visualizing multidimensional cancer genomics data. Genome Med 2013; 5:9. [PMID: 23363777 PMCID: PMC3706894 DOI: 10.1186/gm413] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Cancer genomics projects employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Examples include projects carried out by the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). A crucial step in the extraction of knowledge from the data is the exploration by experts of the different alterations, as well as the multiple relationships between them. To that end, the use of intuitive visualization tools that can integrate different types of alterations with clinical data is essential to the field of cancer genomics. Here, we review effective and common visualization techniques for exploring oncogenomics data and discuss a selection of tools that allow researchers to effectively visualize multidimensional oncogenomics datasets. The review covers visualization methods employed by tools such as Circos, Gitools, the Integrative Genomics Viewer, Cytoscape, Savant Genome Browser, StratomeX and platforms such as cBio Cancer Genomics Portal, IntOGen, the UCSC Cancer Genomics Browser, the Regulome Explorer and the Cancer Genome Workbench.
Collapse
Affiliation(s)
- Michael P Schroeder
- Research Program on Biomedical Informatics - GRIB, Universitat Pompeu Fabra (UPF), Parc de Recerca Biomèdica de Barcelona (PRBB), Dr. Aiguader 88, E-08003 Barcelona, Spain
| | - Abel Gonzalez-Perez
- Research Program on Biomedical Informatics - GRIB, Universitat Pompeu Fabra (UPF), Parc de Recerca Biomèdica de Barcelona (PRBB), Dr. Aiguader 88, E-08003 Barcelona, Spain
| | - Nuria Lopez-Bigas
- Research Program on Biomedical Informatics - GRIB, Universitat Pompeu Fabra (UPF), Parc de Recerca Biomèdica de Barcelona (PRBB), Dr. Aiguader 88, E-08003 Barcelona, Spain ; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| |
Collapse
|
21
|
Castro-Vega LJ, Jouravleva K, Liu WY, Martinez C, Gestraud P, Hupé P, Servant N, Albaud B, Gentien D, Gad S, Richard S, Bacchetti S, Londoño-Vallejo A. Telomere crisis in kidney epithelial cells promotes the acquisition of a microRNA signature retrieved in aggressive renal cell carcinomas. Carcinogenesis 2013; 34:1173-80. [PMID: 23358853 DOI: 10.1093/carcin/bgt029] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Telomere shortening is a major source of chromosome instability (CIN) at early stages during carcinogenesis. However, the mechanisms through which telomere-driven CIN (T-CIN) contributes to the acquisition of tumor phenotypes remain uncharacterized. We discovered that human epithelial kidney cells undergoing T-CIN display massive microRNA (miR) expression changes that are not related to local losses or gains. This widespread miR deregulation encompasses a miR-200-dependent epithelial-to-mesenchymal transition (EMT) that confers to immortalized pre-tumoral cells phenotypic traits of metastatic potential. Remarkably, a miR signature of these cells, comprising a downregulation of miRs with conserved expression in kidney, was retrieved in poorly differentiated aggressive renal cell carcinomas. Our results reveal an unanticipated connection between telomere crisis and the activation of the EMT program that occurs at pre-invasive stages of epithelial cancers, through mechanisms that involve miR deregulation. Thus, this study provides a new rational into how telomere instability contributes to the acquisition of the malignant phenotype.
Collapse
Affiliation(s)
- Luis Jaime Castro-Vega
- UMR3244, Telomeres and Cancer Laboratory, Institut Curie, 26 rue d'Ulm, Paris 75248, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Italiano A, Lagarde P, Brulard C, Terrier P, Laë M, Marques B, Ranchere-Vince D, Michels JJ, Trassard M, Cioffi A, Piperno-Neumann S, Chevreau C, Blay JY, Delcambre C, Isambert N, Penel N, Bay JO, Bonvalot S, Le Cesne A, Coindre JM, Chibon F. Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. Clin Cancer Res 2013; 19:1190-6. [DOI: 10.1158/1078-0432.ccr-12-2970] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Bonnet F, Guedj M, Jones N, Sfar S, Brouste V, Elarouci N, Banneau G, Orsetti B, Primois C, de Lara CT, Debled M, de Mascarel I, Theillet C, Sévenet N, de Reynies A, MacGrogan G, Longy M. An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Med Genomics 2012. [PMID: 23186559 PMCID: PMC3558323 DOI: 10.1186/1755-8794-5-54] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Background Despite entering complete remission after primary treatment, a substantial proportion of patients with early stage breast cancer will develop metastases. Prediction of such an outcome remains challenging despite the clinical use of several prognostic parameters. Several reports indicate that genomic instability, as reflected in specific chromosomal aneuploidies and variations in DNA content, influences clinical outcome but no precise definition of this parameter has yet been clearly established. Methods To explore the prognostic value of genomic alterations present in primary tumors, we performed a comparative genomic hybridization study on BAC arrays with a panel of breast carcinomas from 45 patients with metastatic relapse and 95 others, matched for age and axillary node involvement, without any recurrence after at least 11 years of follow-up. Array-CGH data was used to establish a two-parameter index representative of the global level of aneusomy by chromosomal arm, and of the number of breakpoints throughout the genome. Results Application of appropriate thresholds allowed us to distinguish three classes of tumors highly associated with metastatic relapse. This index used with the same thresholds on a published set of tumors confirms its prognostic significance with a hazard ratio of 3.24 [95CI: 1.76-5.96] p = 6.7x10-5 for the bad prognostic group with respect to the intermediate group. The high prognostic value of this genomic index is related to its ability to individualize a specific group of breast cancers, mainly luminal type and axillary node negative, showing very high genetic instability and poor outcome. Indirect transcriptomic validation was obtained on independent data sets. Conclusion Accurate evaluation of genetic instability in breast cancers by a genomic instability index (G2I) helps individualizing specific tumors with previously unexpected very poor prognosis.
Collapse
Affiliation(s)
- Françoise Bonnet
- Inserm U 916 Institut Bergonié, Université de Bordeaux, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Castéra L, Dehainault C, Michaux D, Lumbroso-Le Rouic L, Aerts I, Doz F, Pelet A, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C. Fine mapping of whole RB1 gene deletions in retinoblastoma patients confirms PCDH8 as a candidate gene for psychomotor delay. Eur J Hum Genet 2012; 21:460-4. [PMID: 22909775 DOI: 10.1038/ejhg.2012.186] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Retinoblastoma (Rb) results from inactivation of both alleles of the RB1 gene located in 13q14.2. Whole-germline monoallelic deletions of the RB1 gene (6% of RB1 mutational spectrum) sometimes cause a variable degree of psychomotor delay and several dysmorphic abnormalities. Breakpoints in 12 Rb patients with or without psychomotor delay were mapped to specifically define the role of chromosomal regions adjacent to RB1 in psychomotor delay. A high-resolution CGH array focusing on RB1 and its flanking region was designed to precisely map the deletion. Comparative analysis detected a 4-Mb critical interval, including a candidate gene protocadherin 8 (PCDH8). PCDH8 is thought to function in signalling pathways and cell adhesion in a central nervous system-specific manner, making loss of PCDH8 one of the probable causes of psychomotor delay in RB1-deleted patients. Consequently, we propose to systematically use high-resolution CGH in cases of partial or complete RB1 deletion encompassing the telomeric flanking region to characterize the putative loss of PCDH8 and to better define genotype/phenotype correlations, eventually leading to optimized genetic counselling and psychomotor follow-up.
Collapse
Affiliation(s)
- Laurent Castéra
- Département de Biologie des Tumeurs, Institut Curie, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Heiliger KJ, Hess J, Vitagliano D, Salerno P, Braselmann H, Salvatore G, Ugolini C, Summerer I, Bogdanova T, Unger K, Thomas G, Santoro M, Zitzelsberger H. Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. Endocr Relat Cancer 2012; 19:409-21. [PMID: 22454401 DOI: 10.1530/erc-11-0387] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
For an identification of novel candidate genes in thyroid tumourigenesis, we have investigated gene copy number changes in a Trk-T1 transgenic mouse model of thyroid neoplasia. For this aim, 30 thyroid tumours from Trk-T1 transgenics were investigated by comparative genomic hybridisation. Recurrent gene copy number alterations were identified and genes located in the altered chromosomal regions were analysed by Gene Ontology term enrichment analysis in order to reveal gene functions potentially associated with thyroid tumourigenesis. In thyroid neoplasms from Trk-T1 mice, a recurrent gain on chromosomal bands 1C4-E2.3 (10.0% of cases), and losses on 3H1-H3 (13.3%), 4D2.3-E2 (43.3%) and 14E4-E5 (6.7%) were identified. The genes Twist2, Ptma, Pde6d, Bmpr1b, Pdlim5, Unc5c, Srm, Trp73, Ythdf2, Taf12 and Slitrk5 are located in these chromosomal bands. Copy number changes of these genes were studied by fluorescence in situ hybridisation on 30 human papillary thyroid carcinoma (PTC) samples and altered gene expression was studied by qRT-PCR analyses in 67 human PTC. Copy number gains were detected in 83% of cases for TWIST2 and in 100% of cases for PTMA and PDE6D. DNA losses of SLITRK1 and SLITRK5 were observed in 21% of cases and of SLITRK6 in 16% of cases. Gene expression was significantly up-regulated for UNC5C and TP73 and significantly down-regulated for SLITRK5 in tumours compared with normal tissue. In conclusion, a global genomic copy number analysis of thyroid tumours from Trk-T1 transgenic mice revealed a number of novel gene alterations in thyroid tumourigenesis that are also prevalent in human PTCs.
Collapse
Affiliation(s)
- Katrin-Janine Heiliger
- Research Unit of Radiation Cytogenetics, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Jung KS, Moon S, Kim YJ, Kim BJ, Park K. Genovar: a detection and visualization tool for genomic variants. BMC Bioinformatics 2012; 13 Suppl 7:S12. [PMID: 22594998 PMCID: PMC3348018 DOI: 10.1186/1471-2105-13-s7-s12] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Along with single nucleotide polymorphisms (SNPs), copy number variation (CNV) is considered an important source of genetic variation associated with disease susceptibility. Despite the importance of CNV, the tools currently available for its analysis often produce false positive results due to limitations such as low resolution of array platforms, platform specificity, and the type of CNV. To resolve this problem, spurious signals must be separated from true signals by visual inspection. None of the previously reported CNV analysis tools support this function and the simultaneous visualization of comparative genomic hybridization arrays (aCGH) and sequence alignment. The purpose of the present study was to develop a useful program for the efficient detection and visualization of CNV regions that enables the manual exclusion of erroneous signals. RESULTS A JAVA-based stand-alone program called Genovar was developed. To ascertain whether a detected CNV region is a novel variant, Genovar compares the detected CNV regions with previously reported CNV regions using the Database of Genomic Variants (DGV, http://projects.tcag.ca/variation) and the Single Nucleotide Polymorphism Database (dbSNP). The current version of Genovar is capable of visualizing genomic data from sources such as the aCGH data file and sequence alignment format files. CONCLUSIONS Genovar is freely accessible and provides a user-friendly graphic user interface (GUI) to facilitate the detection of CNV regions. The program also provides comprehensive information to help in the elimination of spurious signals by visual inspection, making Genovar a valuable tool for reducing false positive CNV results. AVAILABILITY http://genovar.sourceforge.net/.
Collapse
Affiliation(s)
- Kwang Su Jung
- Division of Bio-Medical Informatics, Center for Genome Science, Korea National Institute of Health, Osong, 363-951, Korea
| | | | | | | | | |
Collapse
|
27
|
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012; 14:R11. [PMID: 22247967 PMCID: PMC3496128 DOI: 10.1186/bcr3095] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2011] [Revised: 10/19/2011] [Accepted: 01/16/2012] [Indexed: 01/13/2023] Open
Abstract
INTRODUCTION Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that reproduce the molecular characteristics of their respective clinical tumors. In this work, we analyzed the genomic and gene expression profiles of human BC xenografts and the corresponding patient tumors. METHODS Eighteen BC xenografts were obtained by grafting tumor fragments from patients into Swiss nude mice. Molecular characterization of patient tumors and xenografts was performed by DNA copy number analysis and gene expression analysis using Affymetrix Microarrays. RESULTS Comparison analysis showed that 14/18 pairs of tumors shared more than 56% of copy number alterations (CNA). Unsupervised hierarchical clustering analysis showed that 16/18 pairs segregated together, confirming the similarity between tumor pairs. Analysis of recurrent CNA changes between patient tumors and xenografts showed losses in 176 chromosomal regions and gains in 202 chromosomal regions. Gene expression profile analysis showed that less than 5% of genes had recurrent variations between patient tumors and their respective xenografts; these genes largely corresponded to human stromal compartment genes. Finally, analysis of different passages of the same tumor showed that sequential mouse-to-mouse tumor grafts did not affect genomic rearrangements or gene expression profiles, suggesting genetic stability of these models over time. CONCLUSIONS This panel of human BC xenografts maintains the overall genomic and gene expression profile of the corresponding patient tumors and remains stable throughout sequential in vivo generations. The observed genomic profile and gene expression differences appear to be due to the loss of human stromal genes. These xenografts, therefore, represent a validated model for preclinical investigation of new therapeutic agents.
Collapse
|
28
|
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 2011; 105:1940-8. [PMID: 22146831 PMCID: PMC3251887 DOI: 10.1038/bjc.2011.472] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. Methods: In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enroled in the prospective European INES trials. Results: Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients whose tumours harboured SCA, in the whole population and in trials INES99.1 and INES99.2, in the absence of clinical symptoms (log-rank test, P=0.0001, P=0.04 and P=0.0003, respectively). In multivariate analysis, a SCA genomic profile was the strongest predictor of poorer progression-free survival. Conclusion: In infants with stage 4s MYCN-non-amplified NB, a SCA genomic profile identifies patients who will require upfront treatment even in the absence of other clinical indication for therapy, whereas in infants with localised unresectable NB, a genomic profile characterised by the absence of SCA identifies patients in whom treatment reduction might be possible. These findings will be implemented in a future international trial.
Collapse
|
29
|
CNVAS: Copy Number Variation Analysis System — The analysis tool for genomic alteration with a powerful visualization module. BIOCHIP JOURNAL 2011. [DOI: 10.1007/s13206-011-5311-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Mader M, Simon R, Steinbiss S, Kurtz S. FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. J Clin Bioinforma 2011; 1:20. [PMID: 21884636 PMCID: PMC3164613 DOI: 10.1186/2043-9113-1-20] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2011] [Accepted: 07/28/2011] [Indexed: 12/17/2022] Open
Abstract
Background The rapidly growing amount of array CGH data requires improved visualization software supporting the process of identifying candidate cancer genes. Optimally, such software should work across multiple microarray platforms, should be able to cope with data from different sources and should be easy to operate. Results We have developed a web-based software FISH Oracle to visualize data from multiple array CGH experiments in a genomic context. Its fast visualization engine and advanced web and database technology supports highly interactive use. FISH Oracle comes with a convenient data import mechanism, powerful search options for genomic elements (e.g. gene names or karyobands), quick navigation and zooming into interesting regions, and mechanisms to export the visualization into different high quality formats. These features make the software especially suitable for the needs of life scientists. Conclusions FISH Oracle offers a fast and easy to use visualization tool for array CGH and SNP array data. It allows for the identification of genomic regions representing minimal common changes based on data from one or more experiments. FISH Oracle will be instrumental to identify candidate onco and tumor suppressor genes based on the frequency and genomic position of DNA copy number changes. The FISH Oracle application and an installed demo web server are available at http://www.zbh.uni-hamburg.de/fishoracle.
Collapse
Affiliation(s)
- Malte Mader
- Center for Bioinformatics, University of Hamburg, Bundesstrasse 43, 20146 Hamburg, Germany.
| | | | | | | |
Collapse
|
31
|
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. THE AMERICAN JOURNAL OF PATHOLOGY 2011; 178:881-94. [PMID: 21281820 DOI: 10.1016/j.ajpath.2010.10.039] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Revised: 09/27/2010] [Accepted: 10/21/2010] [Indexed: 11/22/2022]
Abstract
Malignant mesothelioma (MM) is an aggressive tumor with a poor prognosis mainly linked to past asbestos exposure. Murine models of MM based on fiber exposure have been developed to elucidate the mechanism of mesothelioma formation. Genomic alterations in murine MM have now been partially characterized. To gain insight into the pathophysiology of mesothelioma, 16 murine and 35 human mesotheliomas were characterized by array-comparative genomic hybridization and were screened for common genomic alterations. Alteration of the 9p21 human region, often by biallelic deletion, was the most frequent alteration in both species, in agreement with the CDKN2A/CDKN2B locus deletion in human disease and murine models. Other shared aberrations were losses of 1p36.3-p35 and 13q14-q33 and gains of 5p15.3-p13 regions. However, some differences were noted, such as absence of recurrent alterations in mouse regions corresponding to human chromosome 22. Comparison between altered recurrent regions in asbestos-exposed and non-asbestos-exposed patients showed a significant difference in the 14q11.2-q21 region, which was also lost in fiber-induced murine mesothelioma. A correlation was also demonstrated between genomic instability and tumorigenicity of human mesothelioma xenografts in nude mice. Overall, these data show similarities between murine and human disease, and contribute to the understanding of the influence of fibers in the pathogenesis of mesothelioma and validation of the murine model for preclinical testing.
Collapse
|
32
|
Combaret V, Bréjon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A, Bergeron C, Marabelle A, Puisieux A. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer 2011; 56:757-61. [PMID: 21370407 DOI: 10.1002/pbc.22816] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2010] [Accepted: 08/04/2010] [Indexed: 11/05/2022]
Abstract
BACKGROUND Retrospective studies have demonstrated the prognostic impact of genomic profiles in neuroblastoma (NB). Segmental chromosome alterations have been found useful for identifying tumors with a high risk of relapse. As the gain of chromosome arm 17q is the most frequent chromosome alteration reported in NB primary tumors, we evaluated the presence of this 17q gain in the peripheral blood of patients with NB. PROCEDURE Using duplex quantitative real-time PCR, we quantified simultaneously MPO (17q.23.1) and a reference gene, p53, and Survivin (17q25) and p53. MPO and Survivin copy numbers were evaluated as MPO/p53 and Survivin/p53 ratios in 142 serum or plasma samples in which 17q status had been determined by array-based comparative genomic hybridization (aCGH) or multiplex ligation-dependent probe amplification (MLPA). RESULTS In patients <18 months of age, serum-based determination of 17q gain in DNA sequences had good specificity (94.4%) and 58.8% sensitivity (P < 0.001). In contrast, for patients over 18 months of age, the approach exhibited moderate specificity (71.4%) and 51.2% sensitivity (P = ns). Similar results were observed in patients with tumors without MYCN amplification. CONCLUSION Our results show that 17q gain determination in circulating DNA is possible and suggest that this non-invasive test could be useful for very young children when no reliable information on genomic alterations is obtained by aCGH or MPLA analysis of tumor samples This test is complementary to previously developed techniques for detecting circulating MYCN DNA sequences.
Collapse
Affiliation(s)
- Valérie Combaret
- Centre Léon Bérard, Laboratoire de Recherche Translationnelle, Lyon Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Pérot G, Chibon F, Montero A, Lagarde P, de Thé H, Terrier P, Guillou L, Ranchère D, Coindre JM, Aurias A. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. THE AMERICAN JOURNAL OF PATHOLOGY 2011; 177:2080-90. [PMID: 20884963 DOI: 10.2353/ajpath.2010.100104] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Alterations of the p53 pathway are among the most frequent aberrations observed in human cancers. We have performed an exhaustive analysis of TP53, p14, p15, and p16 status in a large series of 143 soft tissue sarcomas, rare tumors accounting for around 1% of all adult cancers, with complex genetics. For this purpose, we performed genomic studies, combining sequencing, copy number assessment, and expression analyses. TP53 mutations and deletions are more frequent in leiomyosarcomas than in undifferentiated pleomorphic sarcomas. Moreover, 50% of leiomyosarcomas present TP53 biallelic inactivation, whereas most undifferentiated pleomorphic sarcomas retain one wild-type TP53 allele (87.2%). The spectrum of mutations between these two groups of sarcomas is different, particularly with a higher rate of complex mutations in undifferentiated pleomorphic sarcomas. Most tumors without TP53 alteration exhibit a deletion of p14 and/or lack of mRNA expression, suggesting that p14 loss could be an alternative genotype for direct TP53 inactivation. Nevertheless, the fact that even in tumors altered for TP53, we could not detect p14 protein suggests that other p14 functions, independent of p53, could be implicated in sarcoma oncogenesis. In addition, both p15 and p16 are frequently codeleted or transcriptionally co-inhibited with p14, essentially in tumors with two wild-type TP53 alleles. Conversely, in TP53-altered tumors, p15 and p16 are well expressed, a feature not incompatible with an oncogenic process.
Collapse
Affiliation(s)
- Gaëlle Pérot
- Institut Curie, Genetics and Biology of Cancers, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Deciphering squamous cell carcinoma using multidimensional genomic approaches. J Skin Cancer 2010; 2011:541405. [PMID: 21234096 PMCID: PMC3017908 DOI: 10.1155/2011/541405] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 10/26/2010] [Indexed: 12/04/2022] Open
Abstract
Squamous cell carcinomas (SqCCs) arise in a wide range of tissues including skin, lung, and oral mucosa. Although all SqCCs are epithelial in origin and share common nomenclature, these cancers differ greatly with respect to incidence, prognosis, and treatment. Current knowledge of genetic similarities and differences between SqCCs is insufficient to describe the biology of these cancers, which arise from diverse tissue origins. In this paper we provide a general overview of whole genome approaches for gene and pathway discovery and highlight the advancement of integrative genomics as a state-of-the-art technology in the study of SqCC genetics.
Collapse
|
35
|
Establishment and Molecular Cytogenetic Characterization of a Cell Culture Model of Head and Neck Squamous Cell Carcinoma (HNSCC). Genes (Basel) 2010; 1:388-412. [PMID: 24710094 PMCID: PMC3966227 DOI: 10.3390/genes1030388] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Revised: 09/30/2010] [Accepted: 10/28/2010] [Indexed: 02/06/2023] Open
Abstract
Cytogenetic analysis of head and neck squamous cell carcinoma (HNSCC) established several biomarkers that have been correlated to clinical parameters during the past years. Adequate cell culture model systems are required for functional studies investigating those potential prognostic markers in HNSCC. We have used a cell line, CAL 33, for the establishment of a cell culture model in order to perform functional analyses of interesting candidate genes and proteins. The cell line was cytogenetically characterized using array CGH, spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH). As a starting point for the investigation of genetic markers predicting radiosensitivity in tumor cells, irradiation experiments were carried out and radiation responses of CAL 33 have been determined. Radiosensitivity of CAL 33 cells was intermediate when compared to published data on tumor cell lines.
Collapse
|
36
|
Gibault L, Pérot G, Chibon F, Bonnin S, Lagarde P, Terrier P, Coindre JM, Aurias A. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 2010; 223:64-71. [PMID: 21125665 DOI: 10.1002/path.2787] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2010] [Revised: 09/09/2010] [Accepted: 09/15/2010] [Indexed: 01/10/2023]
Abstract
Adult soft tissue sarcomas (STS) are rare tumours of mesenchymal lineage. Based on cytogenetic and comparative genomic hybridization (CGH) data, they can be divided into 'STS with simple genomics', displaying a characteristic genetic alteration, and 'STS with complex genomics' (SCG), where multiple genomic alterations occur. This latter group is mostly composed of leiomyosarcomas (LMS) and pleiomorphic undifferentiated tumours previously labelled as 'malignant fibrous histiocytomas' (MFH), corresponding in fact to myxofibrosarcomas (MFS), pleiomorphic liposarcomas/rhabdomyosarcomas (P-LPS, P-RMS), and undifferentiated pleiomorphic sarcomas (UPS). Their pathobiology is still not well understood, leading to challenges in diagnosis and therapeutic management. We report here a comprehensive study encompassing array-CGH and transcriptome analysis data of a large series of 160 SCG. Non-supervised clustering of transcriptome data led to the identification of five groups of tumours, one of them (group A) corresponding to well-differentiated LMS and the other four (B-E) to 'MFH' and poorly differentiated LMS. Welch analysis of transcriptome data in these groups allowed us to retrieve several genes of potential interest. Among them, RB1 alteration is a constant thread in SCG, often associated with RBL2 loss. PTEN tumour suppressor deletion would also stand out as a major recurrent event, especially in groups A, C, and D. The WNT canonical pathway could be potentially involved, as demonstrated by up-regulation of one of its inhibitors, DKK1, in groups D and E, whereas DKK1 is significantly down-regulated in groups A, B, and C. These data suggest a very complex interplay between pathways downstream of PTEN and the WNT canonical pathway, providing new hints about SCG pathobiology and their potential therapeutic targets.
Collapse
Affiliation(s)
- Laure Gibault
- Genetics and Biology of Cancers, Institut Curie, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
37
|
de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2010; 103:1192-200. [PMID: 20877358 PMCID: PMC2967069 DOI: 10.1038/sj.bjc.6605900] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Background: The BRCA2 gene is responsible for a high number of hereditary breast and ovarian cancers, and studies of the BRCA2 biological functions are limited by the lack of models that resemble the patient's tumour features. The aim of this study was to establish and characterise a new human breast carcinoma xenograft obtained from a woman carrying a germline BRCA2 mutation. Methods: A transplantable xenograft was obtained by grafting a breast cancer sample into nude mice. The biological and genetic profiles of the xenograft were compared with that of the patient's tumour using histology, immunohistochemistry (IHC), BRCA2 sequencing, comparative genomic hybridisation (CGH), and qRT–PCR. Tumour response to standard chemotherapies was evaluated. Results: Histological profile identified the tumour as a basal-like triple-negative breast cancer. Targeted BRCA2 DNA sequencing of the xenograft showed the presence of the mutation previously identified in the carrier. Comparative genomic hybridisation array profiles of the primary tumour and the xenograft revealed a high number of similar genetic alterations. The therapeutic assessment of the xenograft showed sensitivity to anthracyclin-based chemotherapy and resistance to docetaxel. The xenograft was also highly sensitive to radiotherapy and cisplatin-based treatments. Conclusions: This study describes a new human breast cancer xenograft obtained from a BRCA2-mutated patient. This xenograft provides a new model for the pre-clinical drug development and for the exploration of the drug response biological basis.
Collapse
Affiliation(s)
- L de Plater
- Preclinical Investigation Unit, Institut Curie - Translational Research Department, Hôpital St Louis, Quadrilatère historique, Porte 13, 1, Ave Claude Vellefaux, Paris 75010, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Gravier E, Pierron G, Vincent-Salomon A, Gruel N, Raynal V, Savignoni A, De Rycke Y, Pierga JY, Lucchesi C, Reyal F, Fourquet A, Roman-Roman S, Radvanyi F, Sastre-Garau X, Asselain B, Delattre O. A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 2010; 49:1125-34. [DOI: 10.1002/gcc.20820] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
|
39
|
Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. ACTA ACUST UNITED AC 2010; 201:102-10. [PMID: 20682394 DOI: 10.1016/j.cancergencyto.2010.05.015] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2010] [Revised: 04/10/2010] [Accepted: 05/28/2010] [Indexed: 12/18/2022]
Abstract
The MUC1 gene is aberrantly overexpressed in approximately 90% of human breast cancers. Several studies have shown that MUC1 overexpression is due to transcriptional regulatory events. However, the importance of gene amplification as a mechanism leading to the increase of MUC1 expression in breast cancer has been poorly characterized. The aim of this study was to evaluate the role of MUC1 gene amplification and protein expression in human breast cancer development. By means of real-time quantitative polymerase chain reaction and immunohistochemical methods, 83 breast tissue samples were analyzed for MUC1 gene amplification and protein expression. This analysis showed MUC1 genomic amplification and a positive association with the histopathological group in 12% (1 out of 8) of benign lesions and 38% (23 out of 60) of primary invasive breast carcinoma samples (P = 0.004). Array-comparative genomic hybridization meta-analysis of 886 primary invasive breast carcinomas obtained from 22 studies showed MUC1 genomic gain in 43.7% (387 out of 886) of the samples. Moreover, we identified a highly statistical significant association between MUC1 gene amplification and MUC1 protein expression assessed by immunohistochemistry and Western blot test (P < 0.0001). In conclusion, this study demonstrated that MUC1 copy number increases from normal breast tissue to primary invasive breast carcinomas in correlation with MUC1 protein expression.
Collapse
Affiliation(s)
- E Lacunza
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Universidad Nacional de La Plata, Argentina
| | | | | | | | | | | |
Collapse
|
40
|
Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010; 12:R63. [PMID: 20712882 PMCID: PMC2949656 DOI: 10.1186/bcr2626] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Revised: 07/07/2010] [Accepted: 08/16/2010] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to explore them for potential new markers. METHODS We first performed a microarray study of three tumors from patients with Cowden disease in the context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray data. RESULTS Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma. CONCLUSIONS These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.
Collapse
Affiliation(s)
- Guillaume Banneau
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
| | - Mickaël Guedj
- Tumor Identity Card program (CIT3), Ligue Nationale Contre le Cancer, 12 rue Corvisart, 75013 Paris, France
| | - Gaëtan MacGrogan
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
- Pathology Department, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
| | - Isabelle de Mascarel
- Pathology Department, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
| | - Valerie Velasco
- Pathology Department, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
| | - Renaud Schiappa
- Tumor Identity Card program (CIT3), Ligue Nationale Contre le Cancer, 12 rue Corvisart, 75013 Paris, France
| | - Valerie Bonadona
- Cancer Genetics Unit, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France
| | - Albert David
- Medical Genetics Unit, CHU de Nantes, 5 allée de l'Île Gloriette, 44000 Nantes, France
| | - Catherine Dugast
- Cancer Genetics Unit, Centre Eugène Marquis, avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France
| | | | - Olivier Ingster
- Medical Genetics Unit, CHU d'Angers, rue Larrey, 49100 Angers, France
| | - Pierre Vabres
- Dermatology Department, CHU de Dijon, 2 boulevard du Maréchal de Lattre de Tassigny, 21000 Dijon, France
| | - Frederic Caux
- Dermatology Department, Hôpital Avicenne, 125 rue Stalingrad, 93000 Bobigny, France
| | - Aurelien de Reynies
- Tumor Identity Card program (CIT3), Ligue Nationale Contre le Cancer, 12 rue Corvisart, 75013 Paris, France
| | - Richard Iggo
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
| | - Nicolas Sevenet
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
- Cancer Genetics Unit, Institut Bergonié, 229 cours de l'Argonne, 33000 Bordeaux, France
| | - Françoise Bonnet
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
- Cancer Genetics Unit, Institut Bergonié, 229 cours de l'Argonne, 33000 Bordeaux, France
| | - Michel Longy
- INSERM U916, Université de Bordeaux, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France
- Cancer Genetics Unit, Institut Bergonié, 229 cours de l'Argonne, 33000 Bordeaux, France
| |
Collapse
|
41
|
Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, Lagarde P, Benard J, Forget S, Blanchard C, Dômont J, Bonvalot S, Guillou L, Leroux A, Mechine-Neuville A, Schöffski P, Laë M, Collin F, Verola O, Carbonnelle A, Vescovo L, Bui B, Brouste V, Sobol H, Aurias A, Coindre JM. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49:560-8. [PMID: 20232483 DOI: 10.1002/gcc.20766] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Desmoid tumors are fibroblastic/myofibroblastic proliferations. Previous studies reported that CTNNB1 mutations were detected in 84% and that mutations of the APC gene were found in several cases of sporadic desmoid tumors lacking CTNNB1 mutations. Forty tumors were analyzed by comparative genomic hybridization (CGH). Karyotype and fluorescence in situ hybridization revealed a nonrandom occurrence of trisomy 8 associated with an increased risk of recurrence. We report the first molecular characterization including a large series of patients. We performed array CGH on frozen samples of 194 tumors, and we screened for APC mutations in patients without CNNTB1 mutation. A high frequency of genomically normal tumors was observed. Four relevant and recurrent alterations (loss of 6q, loss of 5q, gain of 20q, and gain of Chromosome 8) were found in 40 out of 46 tumors with chromosomal changes. Gain of Chromosomes 8 and 20 was not associated with an increased risk of recurrence. Cases with loss of 5q had a minimal common region in 5q22.5 including the APC locus. Alterations of APC, including loss of the entire locus, and CTNNB1 mutation could explain the tumorigenesis in 89% of sporadic desmoids tumors and desmoids tumors occurring in the context of Gardner's syndrome. A better understanding of the pathogenetic pathways in the initiation and progression of desmoid tumors requires studies of 8q and 20q gains, as well as of 6q and 5q losses, and study of the Wnt/beta-catenin pathway.
Collapse
Affiliation(s)
- Sébastien Salas
- Department of Pathology, INSERM U916, Bergonié Institute, 229 cours de l'Argonne, Bordeaux Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Peter M, Stransky N, Couturier J, Hupé P, Barillot E, de Cremoux P, Cottu P, Radvanyi F, Sastre-Garau X. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol 2010; 221:320-30. [PMID: 20527025 DOI: 10.1002/path.2713] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
To investigate whether integration of HPV DNA in cervical carcinoma is responsible for structural alterations of the host genome at the insertion site, a series of 34 primary cervical carcinomas and eight cervical cancer-derived cell lines were analysed. DNA copy number profiles were assessed using the Affymetrix GeneChip Human Mapping 250K Sty array. HPV 16, 18 or 45 integration sites were determined using the DIPS-PCR technique. The genome status at integration sites was classified as follows: no change, amplification, transition normal/gain, normal/loss or gain/LOH. A single HPV integration site was found in 34 cases; two sites were found in seven cases; and three sites in one case (51 sites). Comparison between integration sites and DNA copy number profiles showed that the genome status was altered at 17/51 (33%) integration sites, corresponding to 16/42 cases (38%). Alterations detected were amplification in nine cases, transition normal/loss in four cases, normal/gain in three cases, and gain/LOH in one case. A highly significant association was found between genomic rearrangement and integration of HPV DNA (p < 10(-10)). Activation of the replication origin located in viral integrated sequences in a cell line derived from one of the primary cervical carcinomas induced an increase of the amplification level of both viral and cellular DNA sequences flanking the integration locus. This mechanism may be implicated in the triggering of genome amplification at the HPV integration site in cervical carcinoma. Structural alterations of the host genome are frequently observed at the integration site of HPV DNA in cervical cancer and may act in oncogenesis.
Collapse
Affiliation(s)
- Martine Peter
- Department of Tumour Biology, Institut Curie, F-75248 Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010; 16:781-7. [PMID: 20581836 DOI: 10.1038/nm.2174] [Citation(s) in RCA: 321] [Impact Index Per Article: 22.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2009] [Accepted: 06/01/2010] [Indexed: 12/13/2022]
Abstract
Sarcomas are heterogeneous and aggressive mesenchymal tumors. Histological grading has so far been the best predictor for metastasis-free survival, but it has several limitations, such as moderate reproducibility and poor prognostic value for some histological types. To improve patient grading, we performed genomic and expression profiling in a training set of 183 sarcomas and established a prognostic gene expression signature, complexity index in sarcomas (CINSARC), composed of 67 genes related to mitosis and chromosome management. In a multivariate analysis, CINSARC predicts metastasis outcome in the training set and in an independent 127 sarcomas validation set. It is superior to the Fédération Francaise des Centres de Lutte Contre le Cancer grading system in determining metastatic outcome for sarcoma patients. Furthermore, it also predicts outcome for gastrointestinal stromal tumors (GISTs), breast carcinomas and lymphomas. Application of the signature will permit more selective use of adjuvant therapies for people with sarcomas, leading to decreased iatrogenic morbidity and improved outcomes for such individuals.
Collapse
|
44
|
Gribov A, Sill M, Lück S, Rücker F, Döhner K, Bullinger L, Benner A, Unwin A. SEURAT: visual analytics for the integrated analysis of microarray data. BMC Med Genomics 2010; 3:21. [PMID: 20525257 PMCID: PMC2893446 DOI: 10.1186/1755-8794-3-21] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2010] [Accepted: 06/03/2010] [Indexed: 11/28/2022] Open
Abstract
Background In translational cancer research, gene expression data is collected together with clinical data and genomic data arising from other chip based high throughput technologies. Software tools for the joint analysis of such high dimensional data sets together with clinical data are required. Results We have developed an open source software tool which provides interactive visualization capability for the integrated analysis of high-dimensional gene expression data together with associated clinical data, array CGH data and SNP array data. The different data types are organized by a comprehensive data manager. Interactive tools are provided for all graphics: heatmaps, dendrograms, barcharts, histograms, eventcharts and a chromosome browser, which displays genetic variations along the genome. All graphics are dynamic and fully linked so that any object selected in a graphic will be highlighted in all other graphics. For exploratory data analysis the software provides unsupervised data analytics like clustering, seriation algorithms and biclustering algorithms. Conclusions The SEURAT software meets the growing needs of researchers to perform joint analysis of gene expression, genomical and clinical data.
Collapse
Affiliation(s)
- Alexander Gribov
- Department of Computer Oriented Statistics and Data Analysis, University of Augsburg, Universitätsstr, 14, 86159 Augsburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010; 28:3122-30. [PMID: 20516441 DOI: 10.1200/jco.2009.26.7955] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE Neuroblastoma is characterized by two distinct types of genetic profiles, consisting of either numerical or segmental chromosome alterations. The latter are associated with a higher risk of relapse, even when occurring together with numerical alterations. We explored the role of segmental alterations in tumor progression and the possibility of evolution from indolent to aggressive genomic types. PATIENTS AND METHODS Array-based comparative genomic hybridization data of 394 neuroblastoma samples were analyzed and linked to clinical data. RESULTS Integration of ploidy and genomic data indicated that pseudotriploid tumors with mixed numerical and segmental profiles may be derived from pseudotriploid tumors with numerical alterations only. This was confirmed by the analysis of paired samples, at diagnosis and at relapse, as in tumors with a purely numerical profile at diagnosis additional segmental alterations at relapse were frequently observed. New segmental alterations at relapse were also seen in patients with segmental alterations at diagnosis. This was not linked to secondary effects of cytotoxic treatments since it occurred even in patients treated with surgery alone. A higher number of chromosome breakpoints were correlated with advanced age at diagnosis, advanced stage of disease, with a higher risk of relapse, and a poorer outcome. CONCLUSION These data provide further evidence of the role of segmental alterations, suggesting that tumor progression is linked to the accumulation of segmental alterations in neuroblastoma. This possibility of genomic evolution should be taken into account in treatment strategies of low- and intermediate-risk neuroblastoma and should warrant biologic reinvestigation at the time of relapse.
Collapse
Affiliation(s)
- Gudrun Schleiermacher
- L'Institut National de la Santé et de la Recherche Médicale U830, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Carro A, Rico D, Rueda OM, Díaz-Uriarte R, Pisano DG. waviCGH: a web application for the analysis and visualization of genomic copy number alterations. Nucleic Acids Res 2010; 38:W182-7. [PMID: 20507915 PMCID: PMC2896163 DOI: 10.1093/nar/gkq441] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
waviCGH is a versatile web server for the analysis and comparison of genomic copy number alterations in multiple samples from any species. waviCGH processes data generated by high density SNP-arrays, array-CGH or copy-number calls generated by any technique. waviCGH includes methods for pre-processing of the data, segmentation, calling of gains and losses, and minimal common regions determination over a set of experiments. The server is a user-friendly interface to the analytical methods, with emphasis on results visualization in a genomic context. Analysis tools are introduced to the user as the different steps to follow in an experimental protocol. All the analysis steps generate high quality images and tables ready to be imported into spreadsheet programs. Additionally, for human, mouse and rat, altered regions are represented in a biological context by mapping them into chromosomes in an integrated cytogenetic browser. waviCGH is available at http://wavi.bioinfo.cnio.es.
Collapse
Affiliation(s)
- Angel Carro
- Bioinformatics Unit, Spanish National Cancer Research Centre
| | | | | | | | | |
Collapse
|
47
|
Meyniel JP, Cottu PH, Decraene C, Stern MH, Couturier J, Lebigot I, Nicolas A, Weber N, Fourchotte V, Alran S, Rapinat A, Gentien D, Roman-Roman S, Mignot L, Sastre-Garau X. A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer 2010; 10:222. [PMID: 20492709 PMCID: PMC2891634 DOI: 10.1186/1471-2407-10-222] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Accepted: 05/21/2010] [Indexed: 11/25/2022] Open
Abstract
Background The distinction between primary and secondary ovarian tumors may be challenging for pathologists. The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer. Methods Sixteen paired breast-ovary tumors from patients with a former diagnosis of breast cancer were collected. The genomic profiles of paired tumors were analyzed using the Affymetrix GeneChip® Mapping 50 K Xba Array or Genome-Wide Human SNP Array 6.0 (for one pair), and the data were normalized with ITALICS (ITerative and Alternative normaLIzation and Copy number calling for affymetrix Snp arrays) algorithm or Partek Genomic Suite, respectively. The transcriptome of paired samples was analyzed using Affymetrix GeneChip® Human Genome U133 Plus 2.0 Arrays, and the data were normalized with gc-Robust Multi-array Average (gcRMA) algorithm. A hierarchical clustering of these samples was performed, combined with a dataset of well-identified primary and secondary ovarian tumors. Results In 12 of the 16 paired tumors analyzed, the comparison of genomic profiles confirmed the pathological diagnosis of primary ovarian tumor (n = 5) or metastasis of breast cancer (n = 7). Among four cases with uncertain pathological diagnosis, genomic profiles were clearly distinct between the ovarian and breast tumors in two pairs, thus indicating primary ovarian carcinomas, and showed common patterns in the two others, indicating metastases from breast cancer. In all pairs, the result of the transcriptomic analysis was concordant with that of the genomic analysis. Conclusions In patients with ovarian carcinoma and a previous history of breast cancer, SNP array analysis can be used to distinguish primary and secondary ovarian tumors. Transcriptomic analysis may be used when primary breast tissue specimen is not available.
Collapse
Affiliation(s)
- Jean-Philippe Meyniel
- Department of Translational Research, Institut Curie, 26 rue d'Ulm, 75248 Paris, Cedex 05, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, MacAulay CE, Alvarez CE, Lam WL. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010; 29:73-93. [PMID: 20108112 DOI: 10.1007/s10555-010-9199-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Advances in high-throughput, genome-wide profiling technologies have allowed for an unprecedented view of the cancer genome landscape. Specifically, high-density microarrays and sequencing-based strategies have been widely utilized to identify genetic (such as gene dosage, allelic status, and mutations in gene sequence) and epigenetic (such as DNA methylation, histone modification, and microRNA) aberrations in cancer. Although the application of these profiling technologies in unidimensional analyses has been instrumental in cancer gene discovery, genes affected by low-frequency events are often overlooked. The integrative approach of analyzing parallel dimensions has enabled the identification of (a) genes that are often disrupted by multiple mechanisms but at low frequencies by any one mechanism and (b) pathways that are often disrupted at multiple components but at low frequencies at individual components. These benefits of using an integrative approach illustrate the concept that the whole is greater than the sum of its parts. As efforts have now turned toward parallel and integrative multidimensional approaches for studying the cancer genome landscape in hopes of obtaining a more insightful understanding of the key genes and pathways driving cancer cells, this review describes key findings disseminating from such high-throughput, integrative analyses, including contributions to our understanding of causative genetic events in cancer cell biology.
Collapse
Affiliation(s)
- Raj Chari
- Genetics Unit - Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, Sigaux F, Chan S, Kastner P, Ghysdael J. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 2010; 24:1200-4. [DOI: 10.1038/leu.2010.63] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
50
|
Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28:2151-8. [PMID: 20351326 DOI: 10.1200/jco.2009.26.3814] [Citation(s) in RCA: 327] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine whether the clinical and molecular biologic characteristics of the alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS) subtypes have relevance independent of the presence or absence of the PAX/FOXO1 fusion gene. PATIENTS AND METHODS The fusion gene status of 210 histopathologically reviewed, clinically annotated rhabdomyosarcoma samples was determined by reverse transcriptase polymerase chain reaction. Kaplan-Meier analysis was used to assess event-free survival and overall survival in fusion gene-negative ARMS (ARMSn; n = 39), fusion gene-positive ARMS (ARMSp; n = 94), and ERMS (n = 77). A total of 101 RMS samples were also profiled for whole-genome expression, and 128 were profiled for genomic copy number imbalances. Profiling data were analyzed by supervised and unsupervised methods to compare features related to histopathology and fusion gene status. Results were also projected by meta-analysis techniques across three separate publically available data sets. RESULTS Overall and event-free survival, frequency of metastases, and distribution of site at initial presentation were not significantly different between ARMSn and ERMS. Consistent with this, analysis of gene expression signatures could not reproducibly distinguish ARMSn from ERMS whereas fusion gene-positive cases were distinct. ARMSn and ERMS frequently show whole-chromosome copy number changes, notably gain of chromosome 8 with associated high levels of expression of genes from this chromosome. CONCLUSION The clinical behavior and molecular characteristics of alveolar cases without a fusion gene are indistinguishable from embryonal cases and significantly different from fusion-positive alveolar cases. This implies that fusion gene status irrespective of histology is a critical factor in risk stratification of RMS.
Collapse
Affiliation(s)
- Daniel Williamson
- INSERM Unité 830, Unité de Génétique Somatique, Institut Curie, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|